ASCO前瞻|2018 ASCO年会召开在即，大会热点抢先知

在 "Delivering Discoveries：Expanding the Reach of Precision Medicine" 的会议主题号召下，共有来自全球各个国家的超过 2500 份摘要将在年会期间进行现场展示，还有众多精彩的壁报和口头报告将会在会议中呈现。会议形式包括专题讨论会，主题演讲等，涉及基础和临床科学。

2018 ASCO之重要研究抢先看

本届学术盛宴精彩纷呈，很多重要的研究发现和临床试验成果将会在ASCO年会上首次发布。想知道精彩看点有哪些？小编带您先睹为快：

Abstract LBA1006
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive， PIK3CA-mutant (MUT)， locally advanced or metastatic breast cancer (MBC)： Primary analysis from SANDPIPER.

Abstract LBA1509
Pan-cancer microsatellite instability to predict for presence of Lynch syndrome.

Abstract LBA9000
IMpower131： Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Abstract LBA1
TAILORx： Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive， HER2-negative， node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Abstract LBA2
Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS)： A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).

Abstract LBA3
CARMENA： Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.

Abstract LBA4
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%： Open-label， phase 3 KEYNOTE-042 study.

Abstract LBA3503
A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC)： PRODIGE 7.

Abstract LBA4001
Unicancer GI PRODIGE 24/CCTG PA.6 trial： A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.
Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1) ： A randomized， controlled， multicenter phase III trial.

Abstract LBA4008
Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy： Efficacy and safety in the phase III randomized factorial ASPECT trial.

2018 ASCO之来自中国的声音

随着中国学者在肿瘤临床与科研领域的不断深入与探索，我国肿瘤研究整体水平的国际地位也在逐渐提升，本次大会中国学者将有 6 项重要进展口头汇报：

标题：Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer.（Abstract 5512）

标题：Anlotinib for metastasis soft tissue sarcoma： A randomized， double-blind， placebo-controlled and multi-centered clinical trial.（Abstract 11503）

中国学者除了将在大会进行以上6项重要进展口头汇报以外，还将有30多项学术进展壁报讨论和壁报展示。

关于会议的精彩内容，我们也会随会议进展为您一一呈现，敬请关注。